Certification Rate
100%
Very high DOL cert
A DOL Labor Condition Application record spanning FY2024–2026. Review the filing volume, DOL certification record, and offered-wage context below.
Plainsboro, NJ NAICS: 325412
U.S. Department of Labor's OFLC discloses 29 Labor Condition Application filings naming Novo Nordisk Research & Development US, Inc. from FY2024 through FY2026, drawn directly from DOL's quarterly public disclosure releases. An LCA is the wage-and-working-conditions attestation an employer files with DOL before petitioning USCIS for an H-1B worker: it is a filing record, not a USCIS approval, a job offer, or a confirmed hire, and the count reflects filings, not people, since an employer sponsoring the same role at more than one worksite, or refiling across fiscal years, is counted once per filing. See filing history · Recent LCAs
The verdict
Novo Nordisk Research & Development US, Inc. is listed in 29 DOL LCA filings, more filings than 93% of employer filers in this extract. DOL certified 100% of those LCAs; the median listed offered wage is $141,562. This is not a USCIS approval, hiring, or sponsorship ranking.
According to U.S. Department of Labor OFLC LCA disclosure files (FY2024–FY2026). Based in Plainsboro, NJ.
Novo Nordisk Research & Development US, Inc. vs all U.S. employer filers by LCA volume
Where this employer's disclosed Labor Condition Application count sits among every tracked employer filer (inventory signal, not a sponsorship ranking)
29 8448th of 122824 higher than 114,376 of 122,824 employer filers
Employer filers, banded by disclosed H-1B LCA filing count
Each bar is a band; taller bars hold more employer filers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source U.S. Department of Labor OFLC · FY2024–FY2026
Derived from this employer's disclosed LCAs on file (FY2024–FY2026), title mix and worksite counties, not national boilerplate. LCA filings do not establish USCIS outcomes or confirmed hiring.
Offered-wage span on file: $88,400–$230,000 .
DOL LCA release change
On 29 LCAs with comparable offered vs prevailing wages, Novo Nordisk Research & Development US, Inc. averages about 15.7% above the prevailing wage (national baseline ≈ 17.8%). Dominant PW level on file: Experienced (Level III) (37.9% of LCA filings).
Completed-year LCA counts rose from 1 in FY2024 to 26 in FY2025 (≈26×). Cumulative volume: 29.
Certification Rate
100%
Very high DOL cert
Avg. Salary
$141,562
Above portal avg
Total Workers
29
Small worker count
Compensation range for H-1B positions at Novo Nordisk Research & Development US, Inc.
Wage vs. DOL Minimum
+15.7%
Above DOL floor
national avg +17.8%
Typical DOL Wage Level
Experienced (Level III)
37.9% of LCA filings
Full-Time Positions
100%
Primary Worksite County
LEXINGTON, MA
20.7% of LCA filings
Most frequently listed job titles at Novo Nordisk Research & Development US, Inc.
| Job Title | LCA filings | Avg. Salary |
|---|---|---|
| SR ENGINEER I | 4 | $156,476 |
| Scientist I - Global Research Technologies | 2 | $143,042 |
| SENIOR RESEARCH ASSOCIATE | 2 | $90,200 |
| SCIENTIST I | 2 | $137,540 |
| ASSOCIATE SCIENTIST I | 2 | $111,540 |
| Sr. Data Scientist “ Translational Informatics | 1 | $161,700 |
| Senior Counsel, Intellectual Property | 1 | $230,000 |
| SR COMPUTATIONAL BIOLOGIST | 1 | $166,400 |
| SENIOR SCIENTIST I | 1 | $163,800 |
| SCIENTIST II - RNA GENE THERAPY | 1 | $156,000 |
| SCIENTIST I - GRT | 1 | $146,112 |
| SCIENTIST I - CHEM DEV | 1 | $130,000 |
| Principal Scientist - Translational Research | 1 | $205,000 |
| PROJECT MGR - RESEARCH PROJ MGMT | 1 | $150,800 |
| Cloud & Data Engineer II | 1 | $120,000 |
Cross-state DOL neighbors for Novo Nordisk Research & Development US, Inc. - LCA filing-count and offered-wage axes, outside NJ.
Nearest cross-state employer filers by LCA filing count (29 here; floor ≥10 LCA filings).
Cross-state employer filers with a comparable average listed offered wage ($141,562 here).
Novo Nordisk Research & Development US, Inc. is listed in 29 DOL Labor Condition Application filings covering 29 listed worker positions from FY2024 to FY2026. An LCA is a Labor Department filing record, not confirmation of a USCIS petition, hire, sponsorship, or visa approval.
Among 122,824 employer filers in the DOL disclosure extract, Novo Nordisk Research & Development US, Inc. ranks #8195 by total LCA filing count (29 filings). 114,376 employer filers have fewer disclosed filings in this extract. This is a filing-volume comparison only, not a USCIS approval, hiring, or sponsorship ranking.
Novo Nordisk Research & Development US, Inc. has a 100% DOL certification rate, with 29 out of 29 LCA filings certified. That is the Labor Department step, not a USCIS visa approval rate.
The average offered wage listed in Novo Nordisk Research & Development US, Inc.'s LCAs is $141,562. Listed wages range from $88,400 to $230,000 and are not verified actual compensation.
The top job titles in Novo Nordisk Research & Development US, Inc.'s LCA filing records include SR ENGINEER I, Scientist I - Global Research Technologies, SENIOR RESEARCH ASSOCIATE. The most common listed title is SR ENGINEER I with 4 LCA filings at an average listed offered wage of $156,476. This does not establish actual job openings, hiring, or approved petitions.
Novo Nordisk Research & Development US, Inc. is headquartered in Plainsboro, NJ. Their H-1B workers are distributed across 3 states, with the most positions in MA, CO, CA.
No, Novo Nordisk Research & Development US, Inc. is not classified as H-1B dependent.
Novo Nordisk Research & Development US, Inc. is listed in 1 LCA filings in FY2024 and 2 in FY2026. The average listed offered wage increased from $140,000 to $159,390. This historical filing series does not predict sponsorship, hiring, or visa outcomes.
Disclaimer: Informational only, not professional advice.
ABS(total_petitions) peers first, then a LARGEST-distance pole and a stamp-branched drill, not a fixed Related strip. This page stamps MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 29 LCAs (Δ 0 heavier vs Novo Nordisk Research & Development US, Inc.); CERT-LOCK · WAGE-PREMIUM vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 29 LCAs (Δ 0 heavier vs Novo Nordisk Research & Development US, Inc.); CERT-SOLID · WAGE-PREMIUM vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 29 LCAs (Δ 0 heavier vs Novo Nordisk Research & Development US, Inc.); CERT-LOCK · WAGE-BELOW vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
ABS(total_petitions) peer at 29 LCAs (Δ 0 heavier vs Novo Nordisk Research & Development US, Inc.); CERT-SOLID · WAGE-PREMIUM vs this page's MICRO-BOOK · CERT-LOCK · WAGE-PREMIUM.
NJ pole at 39,678 LCAs stamps MEGA-BOOK · CERT-CLEAN, farthest ABS(total_petitions) contrast from Novo Nordisk Research & Development US, Inc.'s MICRO-BOOK.
Open the NJ state board after the ABS peers. Novo Nordisk Research & Development US, Inc. stamps MICRO-BOOK · CERT-LOCK inside that worksite mix.
Novo Nordisk Research & Development US, Inc.'s WAGE-PREMIUM offered-wage posture needs occupation/state context, not a shared guide card.
What to do with this profile
Use the DOL LCA record for Novo Nordisk Research & Development US, Inc. to compare filing volume and offered wages, not USCIS outcomes.
DOL disclosure data only. Not legal advice, sponsorship guarantees, or visa eligibility.
Every figure on PlainVisa is rendered directly from federal source data, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error. Data current as of 2026-09-09.